Page last updated: 2024-11-12
af 150
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
1-methylpiperidine-4-spiro-(2'-methylthiazoline): a selective and efficacious M1 agonist no further information [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10176415 |
| SCHEMBL ID | 1328277 |
| MeSH ID | M0179184 |
Synonyms (11)
| Synonym |
|---|
| 1-thia-3,8-diazaspiro(4.5)dec-2-ene, 2,8-dimethyl- |
| 138300-72-8 |
| af-150(s) |
| af 150(s) |
| 1-methylpiperidine-4-spiro-(2'-methylthiazoline) |
| 2,8-dimethyl-1-thia-3,8-diazaspiro[4.5]dec-2-ene |
| L007073 |
| SCHEMBL1328277 |
| 2,8-dimethyl-1-thia-3,8-diaza-spiro[4.5]dec-2-ene |
| af150(s) |
| VGGGBQVTSUMURJ-UHFFFAOYSA-N |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Notably, these compounds show a high bioavailability and a remarkable preference for the brain vs." | ( AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. Bar-Ner, RH; Brandeis, R; Fisher, A; Kliger-Spatz, M; Marcovitch, I; Natan, N; Pittel, Z; Sonego, H, ) | 0.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 60.22
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (60.22) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (25.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||